Introduction {#sec1-0300060520901872}
============

Endotracheal intubation is the most commonly used airway management method during general anaesthesia because it is safe for the patients and convenient for the anaesthetists. Moreover, the use of a cuffed tube protects the lungs from aspiration of stomach contents and importantly, also prevents positive pressure ventilation due to leakage. The procedure involves insertion of a plastic or hard metal laryngoscope into the patient's mouth followed by a series of manipulations including lifting of the epiglottis and then placement of the endotracheal tube (ETT) into the patient's trachea between the V-shaped vocal cords. These manipulations in the patient's mouth can cause transient irritation to the local mucosa of the oropharynx or trachea.^[@bibr1-0300060520901872]^ In addition, several studies have reported that during inhalational anaesthesia with nitrous oxide (N~2~O), diffusion of the gas into the ETT cuff can increase the cuff pressure which can also induce tracheal mucosal injury.^[@bibr2-0300060520901872],[@bibr3-0300060520901872]^ These injuries can influence the extubation process and be responsible for complications such as excessive coughing or bucking on tube. Indeed, coughing induced by the ETT can be dangerous because it can cause increased cerebral pressure, intraocular pressure, intraabdominal and/or systemic blood pressure which may result in myocardial ischemia, surgical bleeding, tachycardia, bronchospasm and other life-threatening complications.^[@bibr4-0300060520901872][@bibr5-0300060520901872]--[@bibr6-0300060520901872]^

A number of methods have been used to reduce complications during the extubation process such as intravenous drugs or extubation under deep anesthesia.^[@bibr4-0300060520901872],[@bibr7-0300060520901872],[@bibr8-0300060520901872]^ However, these methods may themselves cause complications, such as general anaesthesia-delayed awakening.^[@bibr4-0300060520901872]^ The use of a topical local anaesthetic during the extubation process has been suggested as a possible alternative that may act to suppress cough while preventing delayed awakening.^[@bibr9-0300060520901872],[@bibr10-0300060520901872]^ One of the methods used to apply local anaesthetic to the mucosa uses an intracuff injection of lidocaine.^[@bibr11-0300060520901872],[@bibr12-0300060520901872]^ In addition to providing a local anaesthetic effect and suppressing complications during extubation, it also prevents diffusion of inhalational anaesthetics into the ETT cuff.^[@bibr11-0300060520901872],[@bibr13-0300060520901872],[@bibr14-0300060520901872]^ Furthermore, the addition of sodium bicarbonate (NaHCO~3~) (i.e., alkalinisation) increases diffusion across the cuff and enables low doses of lidocaine to be used effectively.^[@bibr10-0300060520901872]^

To our knowledge, no systematic review has been performed to evaluate the efficacy of intracuff lidocaine on preventing ETT-related cough on tube. Therefore, we conducted a systematic review and meta-analysis according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) regulations ^[@bibr15-0300060520901872]^to evaluate the efficacy of intracuff lidocaine in reducing cough on tube and some other common ETT side effects during the extubation process.

Methods {#sec2-0300060520901872}
=======

The Cochrane Library, PubMed and EMBASE databases were systematically searched for randomized controlled clinical trials (RCTs) published before June 30, 2019 that investigated the use of intracuff alkalinized or non-alkalinized lidocaine for the prevention of cough on tube and other intubation-related complications (i.e., hoarseness, agitation, restlessness, dysphonia) on extubation. In addition, the reference lists of all included studies were checked for any potential additional publications. Key words/terms in both AND and OR combinations included: lidocaine; lignocaine; xylocaine; coughing; hoarseness; dysphonia; agitation; restlessness; emergency; general anaesthesia; endotracheal tube; extubation.

For a published report to be included in the meta-analysis, it had to fulfil the following criteria: (1) be a RCT; (2) be an English language article; (3) have investigated the efficacy of intracuff lidocaine for reducing coughing on tube and other intubation-related complications on extubation. Studies with small sample sizes and those with emergency operations were excluded as were duplicate publications, reviews, editorials, abstracts, comments, case reports, meetings and those involving animals. Two reviewers \[F.P., H.Y.\] independently screened the papers from their titles and abstracts and selected relevant studies. The same two reviewers \[F.P., H.Y.\] independently extracted data from the studies according to a prespecified protocol with any disagreement settled by a third reviewer \[M.W.\].

The following items were extracted: name of the first author; publication year; country; type of surgery; American Society of Anaesthesiologists (ASA) status; ^[@bibr16-0300060520901872]^ sample size; sex; age; tube size; anaesthetic; ETT intervention; incidence of coughing, hoarseness, agitation/restlessness, and dysphonia related to ETT during the extubation process).

The primary outcome of the meta-analysis was the incidence of coughing on tube. The secondary outcome was the incidences of hoarseness, agitation/restlessness and dysphonia during the extubation process. Control groups included patients with intracuff saline or intracuff air. Patients were separated into two subgroups based on if they had received NaHCO~3~ with the lidocaine (i.e., 'alkalinized lidocaine' or 'non-alkalinized lidocaine').

The study was approved by the Ethics Committee of the Affiliated Hospital of Southwest Medical University, Luzhou, China and because this was a meta-analysis of previously published articles, ethical approval was not required.

Statistical analyses {#sec3-0300060520901872}
--------------------

The meta-analysis was performed using Review Manager (RevMan) \[Computer program\] Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014 and a sensitivity analysis was performed using the soft-ware package Stata version12 (Stata Corp, College Station, Texas). A *P*-value \<0.05 was considered to indicate statistical significance.

The level of evidence quality of each study was estimated according to the guidelines of Grading of Recommendations, Assessment, Development, and Evaluation (GRADE).^[@bibr17-0300060520901872]^ The GRADE approach applies a sequential assessment of the evidence quality and a subsequent judgment on the strength of the recommendations. The evidence grades were classified into four categories: (1) high grade (further research is unlikely to change confidence in the effect estimate); (2) moderate grade (further research is likely to alter confidence in the effect estimate and may change the estimate); (3) low grade (further research is very likely to alter confidence in the effect estimate significantly and to change the estimate); (4) very low grade (any effect estimate is uncertain). Cochran\'s Q test and Higgins\' I^2^ statistical test were used to assess the statistical heterogeneity of the pooled results. If I^2^ statistic ≥50% and *P* \< 0.05, a random effects model was applied to the data. If no heterogeneity was observed, a fixed effect model was to be used.

Data were pooled from all eligible RCTs and the Mantel--Haenszel method was used to calculate the risk ratio (RR) with 95% CIs for these dichotomous outcomes. A pooled estimate of RR was computed using the DerSimonian and Laird random-effects model. ^[@bibr18-0300060520901872],[@bibr19-0300060520901872]^ This model provides an appropriate estimate of the average treatment effect when studies are statistically heterogeneous, and it typically yields relatively wide CIs resulting in a more conservative statistical claim. In addition, a sensitivity analysis was used to assess the robustness of the results and Begg's funnel plot was used to assess potential publication bias.

Results {#sec4-0300060520901872}
=======

The literature search identified 864 articles from which 11 articles ultimately met the eligibility criteria ([Figure 1](#fig1-0300060520901872){ref-type="fig"}). The main features of the 11 studies that involved 843 patients are summarized in [Table 1](#table1-0300060520901872){ref-type="table"}. Of the 11 studies, three were performed in France, two in India and one in each of the following countries: Canada; Kingdom of Saudi Arabia; Brazil, Turkey; Tunisia; Ireland. With the exception of one study in children,^[@bibr21-0300060520901872]^ all studies involved adult patients.

![Flow diagram of included and excluded studies.](10.1177_0300060520901872-fig1){#fig1-0300060520901872}

###### 

Characteristics of the 11 randomized controlled clinical trials included in the meta-analysis investigating the efficacy of intracuff lidocaine in reducing coughing and other endotracheal tube side effects.

![](10.1177_0300060520901872-table1)

  Study                                                   Country   N (M/F)       Age (y)   Surgery (ASA status)                          Tube size (mm)          Anaesthetic                      Endotracheal tube intervention                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  ------------------------------------------------------- --------- ------------- --------- --------------------------------------------- ----------------------- -------------------------------- --------------------------------------------------------------------- ----------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------
  D\'Aragon et al. (2013) ^[@bibr10-0300060520901872]^    Canada    116 (0/116)   Mean 44   Gynaecological (I-II)                         7                       NR                               Fentanyl, propofol, rocuronium                                        50% O~2~, desflurane, fentanyl, rocuronium      30^[\#](#table-fn8-0300060520901872){ref-type="table-fn"}^/28^[¥](#table-fn9-0300060520901872){ref-type="table-fn"}^                                                                                                                          29^[\#](#table-fn8-0300060520901872){ref-type="table-fn"}^/29^[¥](#table-fn9-0300060520901872){ref-type="table-fn"}^   --
  Estebe et al. (2005)^[@bibr20-0300060520901872]^        France    60(13/47)     Mean 48   Thyroidectomy (I-II)                          M = 7--7.5F = 6.5--7    Alprazolam                       Propofol, sufentanil, atracurium                                      50% O~2~, 50% air, sevoflurane, sufentanil      20^[λ](#table-fn10-0300060520901872){ref-type="table-fn"}^/20^β , λ^                                                                                                                                                                          --                                                                                                                     20^[λ](#table-fn10-0300060520901872){ref-type="table-fn"}^
  Ahmady et al. (2013)^[@bibr21-0300060520901872]^        KSA       50 (31/19)    Mean8     Dental (I-II)                                 Age/4+ 3                Diazepam                         Fentanyl, propofol, rocuronium                                        50% O~2~, sevoflurane, fentanyl                 25                                                                                                                                                                                                                                            25                                                                                                                     --
  Shroff & Patil (2009) ^[@bibr22-0300060520901872]^      India     150 (51/99)   Mean 37   Elective (I-II)                               NR                      NR                               Opioid, propofol, benzodiazepine, non-depolarizing muscle relaxant.   60%N~2~O                                        50^[γ](#table-fn5-0300060520901872){ref-type="table-fn"}^                                                                                                                                                                                     50                                                                                                                     50
  Jaichandran et al. (2009)^[@bibr23-0300060520901872]^   India     75 (61/14)    Mean 32   Eye (I-II)                                    M = 8--8.5F =  7--7.5   Glycopyrrolate and pentazocine   Propofol, vecuronium                                                  70% N~2~O, isoflurane, vecuronium               25^γ , δ^                                                                                                                                                                                                                                     25^[δ](#table-fn11-0300060520901872){ref-type="table-fn"}^                                                             25^[δ](#table-fn11-0300060520901872){ref-type="table-fn"}^
  Navarro et al. (2012)^[@bibr24-0300060520901872]^       Brazil    50 (13/37)    \>18      Gynaecological/ orthopaedic/ plastic (I-II)   M = 8F = 7.5            Midazolam                        NR                                                                    60% N~2~O, isoflurane, sufentanil, rocuronium   25^[δ](#table-fn11-0300060520901872){ref-type="table-fn"}^                                                                                                                                                                                    25^[δ](#table-fn11-0300060520901872){ref-type="table-fn"}^                                                             
  Estebe et al. (2004)^[@bibr25-0300060520901872]^        France    60 (39/21)    Mean 50   Spinal (I-III)                                M = 7--7.5F = 6.5--7    Hydroxyzine                      Thiopental, sufentanil, rocuronium                                    70% N~2~O, isoflurane, sufentanil, rocuronium   20^λ^/20^[δ](#table-fn11-0300060520901872){ref-type="table-fn"}^                                                                                                                                                                              --                                                                                                                     20^[λ](#table-fn10-0300060520901872){ref-type="table-fn"}^
  Estebe et al. (2002)^[@bibr26-0300060520901872]^        France    75 (40/35)    Mean 46   Spinal (I-III)                                NR                      NR                               Standard anaesthetics                                                 70%N~2~O, isoflurane, sufentanil, rocuronium    25^[λ](#table-fn10-0300060520901872){ref-type="table-fn"}^                                                             25^[λ](#table-fn10-0300060520901872){ref-type="table-fn"}^                                                             --                                                                                                                     25^[λ](#table-fn10-0300060520901872){ref-type="table-fn"}^
  Altintas et al. (2000)^[@bibr12-0300060520901872]^      Turkey    70 (31/39)    Mean 30   Plastic (I-II)                                M = 8F = 7              None                             Fentanyl, propofol atracurium                                         50% N~2~O, isoflurane, fentanyl                                                                                                                                        36^[∞](#table-fn6-0300060520901872){ref-type="table-fn"}^                                                              34                                                                                                                     
  Bousselmi et al. (2014)^[@bibr27-0300060520901872]^     Tunisia   80 (49/31)    Mean 49   Elective (I-III)                              M = 7.5F = 7            NR                               Propofol, remifentanil, cisatracurium                                 propofol and remifentanil, cisatracurium                                                                                                                               20^[\#](#table-fn8-0300060520901872){ref-type="table-fn"}^/20^[¥](#table-fn9-0300060520901872){ref-type="table-fn"}^   20^[\#](#table-fn8-0300060520901872){ref-type="table-fn"}^/20^[¥](#table-fn9-0300060520901872){ref-type="table-fn"}^   
  Fagan et al. (2000)^[@bibr28-0300060520901872]^         Ireland   57 (NR)       Mean 40   Orthopaedic/urological/plastic (I-II)         M = 8.5F = 7.5          Diazepam                         Fentanyl, propofol, vecuronium                                        65% N~2~O, isoflurane, fentanyl                                                                                                                                        18^[ε](#table-fn7-0300060520901872){ref-type="table-fn"}^                                                              18                                                                                                                     21

Abbreviations: KSA, Kingdom of Saudi Arabia; ASA, American Society of Anaesthesiologists^[@bibr16-0300060520901872]^; M, male; F, female; NR, not recorded; N~2~O, nitrous oxide.

\*Lidocaine 2%, sodium bicarbonate 8.4% (unless otherwise specified).

Lidocaine 2%.

Lidocaine 2%, sodium bicarbonate 1.4%.

Lidocaine 2%, sodium bicarbonate 7.5%.

Lidocaine 10%.

Lidocaine 4%.

Saline on larynx.

Lidocaine 2% on larynx.

Sterile water used as a lubricant on the tracheal tube.

Water soluble gel used as a lubricant on the tracheal tube.

By comparison with controls, prevention of intubation-related complications was investigated in eight studies using intracuff alkalinized lidocaine^[@bibr10-0300060520901872],[@bibr20-0300060520901872][@bibr21-0300060520901872][@bibr22-0300060520901872][@bibr23-0300060520901872][@bibr24-0300060520901872][@bibr25-0300060520901872]--[@bibr26-0300060520901872]^ and four studies using intracuff non-alkalinized lidocaine.^[@bibr12-0300060520901872],[@bibr26-0300060520901872][@bibr27-0300060520901872]--[@bibr28-0300060520901872]^ In addition, one controlled study included the effects of intracuff alkalinized lidocaine and intracuff non-alkalinized lidocaine.^[@bibr26-0300060520901872]^ With the exception of two studies, one that used 4% lidocaine^[@bibr28-0300060520901872]^ and the other 10% lidocaine,^[@bibr12-0300060520901872]^ all studies used 2% lidocaine instilled into the endotracheal tube cuff. Six studies used 8.4% NaHCO~3~¸^[@bibr10-0300060520901872],[@bibr20-0300060520901872],[@bibr21-0300060520901872],[@bibr24-0300060520901872][@bibr25-0300060520901872]--[@bibr26-0300060520901872]^ two studies used 7.5% NaHCO~3~^[@bibr22-0300060520901872],[@bibr23-0300060520901872]^ and one study included a subgroup who received 1.4% NaHCO~3.~^[@bibr20-0300060520901872]^

Eight studies used endotracheal tube cuffs inflated with saline as control,^[@bibr10-0300060520901872],[@bibr12-0300060520901872],[@bibr21-0300060520901872][@bibr22-0300060520901872][@bibr23-0300060520901872]--[@bibr24-0300060520901872],[@bibr27-0300060520901872],[@bibr28-0300060520901872]^ six studies used cuffs injected with air as control,^[@bibr20-0300060520901872],[@bibr22-0300060520901872],[@bibr23-0300060520901872],[@bibr25-0300060520901872],[@bibr26-0300060520901872],[@bibr28-0300060520901872]^ and three studies used both saline and air as control.^[@bibr22-0300060520901872],[@bibr23-0300060520901872],[@bibr28-0300060520901872]^ In addition, five studies investigated the additional use of lubricants on the tube cuff (i.e., lidocaine, saline or water-soluble gel)^[@bibr20-0300060520901872],[@bibr23-0300060520901872][@bibr24-0300060520901872][@bibr25-0300060520901872]--[@bibr26-0300060520901872]^ and two studies investigated the effects of additional sprays on the larynx (i.e., 2% lidocaine or saline).^[@bibr10-0300060520901872],[@bibr27-0300060520901872]^

There were differences between studies in anaesthetic techniques. For example, six studies^[@bibr20-0300060520901872],[@bibr21-0300060520901872],[@bibr23-0300060520901872][@bibr24-0300060520901872]--[@bibr25-0300060520901872],[@bibr28-0300060520901872]^ premedicated their patients and N~2~O was administered for anaesthesia maintenance in seven studies.^[@bibr12-0300060520901872],[@bibr22-0300060520901872][@bibr23-0300060520901872][@bibr24-0300060520901872][@bibr25-0300060520901872]--[@bibr26-0300060520901872],[@bibr28-0300060520901872]^ All of these differences contributed to the statistical heterogeneity of the studies.

In terms of the primary outcome, the incidence of coughing on tube, the aggregate outcome of the 11 studies favoured the lidocaine groups over the control groups (RR, 0.45; 95% CI, 0.31, 0.65; *P* \< 0.0001; I^2^ = 86%) ([Figure 2](#fig2-0300060520901872){ref-type="fig"}). The results of the subgroup analyses showed that by companion with controls, the application of intracuff alkalinized lidocaine was more effective than that of non-alkalinized intracuff lidocaine in reducing the incidence of coughing on tube (RR: 0.40; 95% CI: 0.25, 0.63; *P* \< 0.0001; I^2^ = 83% and (RR: 0.58; 95% CI: 0.30, 1.10; *P* \< 0.0001; I^2^ = 85%), respectively) ([Figure 2](#fig2-0300060520901872){ref-type="fig"}).

![Forest plot evaluating the effects of intracuff lidocaine (alkalinized and non-alkalinized) by comparison with control groups (saline or air) on the incidence of coughing during endotracheal tube intubation.\
Abbreviations: Alk-lidocaine, alkalinized lidocaine; Non-alk-lidocaine, non-alkalinized lidocaine; Estebe 2002 (1) and (2), this study included alkalinized and non- alkalinized groups; M--H, Mantel--Haenszel; df, degrees of freedom; experimental, lidocaine.](10.1177_0300060520901872-fig2){#fig2-0300060520901872}

The analysis was repeated after excluding three studies that had included high-risk patient groups (i.e., children,^[@bibr21-0300060520901872]^ smokers^[@bibr24-0300060520901872]^ and patients with hyperactive airways^[@bibr23-0300060520901872]^). There was no significant difference in the outcome; the lidocaine groups were more effective than the control groups in reducing the incidence of coughing on tube ([Figure 3](#fig3-0300060520901872){ref-type="fig"}).

![Forest plot evaluating the effects of intracuff lidocaine (alkalinized and non-alkalinized) by comparison with control groups (saline or air) on the incidence of coughing during endotracheal tube intubation after excluding three studies involving high-risk patient groups.^[@bibr21-0300060520901872],[@bibr23-0300060520901872],[@bibr24-0300060520901872]^\
Abbreviations: Alk-lidocaine, alkalinized lidocaine; Non-alk-lidocaine, non-alkalinized lidocaine; Estebe 2002 (1) and (2), this study included alkalinized and non- alkalinized groups; M--H, Mantel--Haenszel; df, degrees of freedom; experimental, lidocaine.](10.1177_0300060520901872-fig3){#fig3-0300060520901872}

Studies that assessed hoarseness, agitation/restlessness and/or dysphonia are shown in [Table 2](#table2-0300060520901872){ref-type="table"}. Analysis of the secondary outcome showed that by comparison with controls, intracuff administration of alkalinized lidocaine or non-alkalinized lidocaine produced a significant reduction in the incidence of other intubation-related complications ([Table 3](#table2-0300060520901872){ref-type="table"})

###### 

Studies that assessed the efficacy of intracuff lidocaine on the incidence of hoarseness, agitation/restlessness and dysphonia during the extubation process.

![](10.1177_0300060520901872-table2)

  Study                                                                                                       Total No. patients   No receiving lidocaine   Hoarseness   Agitation/Restlessness   Dysphonia
  ----------------------------------------------------------------------------------------------------------- -------------------- ------------------------ ------------ ------------------------ -----------
  Alkalinized Lidocaine                                                                                                                                                                           
   D\'Aragon et al. (2013)^[@bibr10-0300060520901872]^                                                        116                  58                       X            √                        X
   Estebe, et al. (2005)^[@bibr20-0300060520901872]^                                                          60                   40                       √            √                        √
   Ahmady, et al. (2013)^[@bibr21-0300060520901872]^                                                          50                   25                       √            X                        X
   Shroff & Patil (2009) ^[@bibr22-0300060520901872]^                                                         150                  50                       √            √                        X
   Jaichandran et al. (2009)^[@bibr23-0300060520901872]^                                                      75                   25                       X            X                        X
   Navarro et al. (2012)^[@bibr24-0300060520901872]^                                                          50                   25                       √            X                        X
   Estebe, et al. (2004)^[@bibr25-0300060520901872]^                                                          60                   40                       √            √                        √
   [\*](#table-fn12-0300060520901872){ref-type="table-fn"}Estebe, et al. (2002)^[@bibr26-0300060520901872]^   75                   25                       √            √                        √
  Non-alkalinized Lidocaine                                                                                                                                                                       
   [\*](#table-fn12-0300060520901872){ref-type="table-fn"}Estebe, et al. (2002)^[@bibr26-0300060520901872]^   75                   25                       √            √                        √
   Altintas, et al. (2000)^[@bibr12-0300060520901872]^                                                        70                   36                       X            X                        X
   Bousselmi, et al. (2014)^[@bibr27-0300060520901872]^                                                       80                   40                       X            X                        √
   Fagan et al. (2000)^[@bibr28-0300060520901872]^                                                            57                   18                       X            X                        X

\*Estebe et al, 2002 included alkalinized and non- alkalinized groups.

###### 

Efficacy of intracuff lidocaine in the reduction of other complications during the extubation process.

![](10.1177_0300060520901872-table3)

  Secondary outcomes                 No. Studies                                                                                                                                                                                                                   No. patients   Risk ratio (95% CIs)   Statistical significance
  ---------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- ---------------------- --------------------------
  Hoarseness (overall)               [\*](#table-fn13-0300060520901872){ref-type="table-fn"}6^[@bibr20-0300060520901872][@bibr21-0300060520901872]--[@bibr22-0300060520901872],[@bibr24-0300060520901872][@bibr25-0300060520901872]--[@bibr26-0300060520901872]^   445            0.21 (0.02, 1.57)      *P* \< 0.001
   alkalinized lidocaine             6^[@bibr20-0300060520901872][@bibr21-0300060520901872]--[@bibr22-0300060520901872],[@bibr24-0300060520901872][@bibr25-0300060520901872]--[@bibr26-0300060520901872]^                                                          205            0.44 (0.34, 0.57)      *P* \< 0.01
   non- alkalinized lidocaine        1^[@bibr26-0300060520901872]^                                                                                                                                                                                                 25             0.05 (0.01, 0.36)      *P* \< 0.01
  Agitation/Restlessness (overall)   [\*](#table-fn13-0300060520901872){ref-type="table-fn"}5^[@bibr10-0300060520901872],[@bibr20-0300060520901872],[@bibr22-0300060520901872],[@bibr25-0300060520901872],[@bibr26-0300060520901872]^                              461            0.24 (0.17, 0.43)      *P* = 0.02
   alkalinized lidocaine             5^[@bibr10-0300060520901872],[@bibr20-0300060520901872],[@bibr22-0300060520901872],[@bibr25-0300060520901872],[@bibr26-0300060520901872]^                                                                                     213            0.07 (0.02, 0.29)      *P \< *0.01
   non- alkalinized lidocaine        1^[@bibr26-0300060520901872]^                                                                                                                                                                                                 25             0.13 (0.02, 0.93)      *P* = 0.04
  Dysphonia (overall)                [\*](#table-fn13-0300060520901872){ref-type="table-fn"}4^[@bibr20-0300060520901872],[@bibr25-0300060520901872][@bibr26-0300060520901872]--[@bibr27-0300060520901872]^                                                         275            0.28 (0.14, 0.51)      *P* \< 0.01
   alkalinized lidocaine             3^[@bibr20-0300060520901872],[@bibr25-0300060520901872],[@bibr26-0300060520901872]^                                                                                                                                           105            0.16 (0.06, 0.46)      *P* \< 0.01
   non- alkalinized lidocaine        2^[@bibr26-0300060520901872],[@bibr27-0300060520901872]^                                                                                                                                                                      65             0.33 (0.25, 0.51)      *P* \< 0.0001

\*Estebe et al, 2002 included alkalinized and non- alkalinized groups.

According to the GRADE recommendations for level of evidence quality, the results from the 11 studies were classed as 'low grade'.^[@bibr19-0300060520901872]^ In addition, the results of a Begg's funnel plot showed asymmetry in the scatter of studies indicating publication bias ([Figure 4](#fig4-0300060520901872){ref-type="fig"}). However, the results of a sensitivity analysis showed that the omission of each study in the analysis of RRs did not significantly alter the overall results indicating that our pooled analysis from 11 studies was robust ([Figure 5](#fig5-0300060520901872){ref-type="fig"}).

![Funnel plot for evaluation of potential publication bias.\
Abbreviations: Alk-lido, alkalinized lidocaine; Non-alk-lido, non-alkalinized lidocaine; RR, risk ratio; SE, standard error.](10.1177_0300060520901872-fig4){#fig4-0300060520901872}

![Sensitivity analysis to confirm the robustness of the results by removing one study at a time. Each circle and dotted line represent the risk ratio (RR) and 95% CIs with the corresponding study omitted from the overall result.](10.1177_0300060520901872-fig5){#fig5-0300060520901872}

Discussion {#sec5-0300060520901872}
==========

Although a previous systematic review and meta-analysis has investigated the effects of intracuff lidocaine on postoperative sore throat,^[@bibr29-0300060520901872]^ no systematic review has previously been performed to evaluate the efficacy of intracuff lidocaine on preventing ETT-related coughing a potentially life-threatening complication which can occur during the extubation process.^[@bibr4-0300060520901872][@bibr5-0300060520901872]--[@bibr6-0300060520901872]^

The results of this meta-analysis of 11 RCTs involving 843 patients showed that the administration of alkalinized or non-alkalinized lidocaine to endotracheal tube cuffs significantly reduced coughing on tube and other intubation-related complications (i.e., hoarseness, agitation/restlessness and/or dysphonia) during the extubation process. In addition, by comparison with controls, intracuff administration of alkalinized lidocaine tended to be more effective than non-alkalinized lidocaine. Importantly, the outcome was similar when studies with high risk patients (i.e., children, smokers and those with hyperactive airways)^[@bibr21-0300060520901872],[@bibr23-0300060520901872],[@bibr24-0300060520901872]^ were excluded from the analysis. However, according to GRADE recommendations the studies were classed as 'low level of evidence quality' and results from a funnel plot indicated potential publication bias.

Many different factors in these studies contributed to their heterogeneity. Firstly, the patients' characteristics varied from study to study. For example, one study only included female patients^[@bibr10-0300060520901872]^ and another only children.^[@bibr21-0300060520901872]^ In addition, one study focused on patients with hyperactive airways^[@bibr23-0300060520901872]^ and another on smokers.^[@bibr24-0300060520901872]^ Secondly, patients underwent different types of surgeries and were subjected to various anaesthetic strategies. For instance, the anaesthetic interventions varied in their use of different endotracheal tube sizes, pre-medications, and techniques for maintenance of anaesthesia. Finally, the concentration of lidocaine with or without alkalinisation differed among studies as did the control groups (i.e., saline or air) and the concentration of NaHCO~3~. Nevertheless, the results of a sensitivity analysis of these data showed that omission of each study did not significantly alter the overall results of this meta-analysis indicating that our findings were not driven by any single study and the analysis was robust.

The study had several limitations. For example, only 11 studies were included in the analysis and of these studies, eight used intracuff alkalinized lidocaine and four intracuff non-alkalinized lidocaine. Although all studies assessed the effects of lidocaine on coughing, few studies assessed the effects of non-alkalinized lidocaine on the other ETT-related complications. Additionally, only one studied included alkalinized lidocaine and non-alkalinized lidocaine groups. Moreover, the sample sizes in all studies were small. Furthermore, all studies in this analysis were classed as 'low quality' according to GRADE recommendations and the funnel plot indicated publication bias. Therefore, more prospective, controlled, comparative studies involving large numbers of patients are required to confirm these results.

In summary, the results of this meta-analysis suggest that intracuff application of lidocaine, alkalinized or non-alkalinized, can be helpful in the prevention of coughing and other intubation-related complications during the extubation process. However, further research is required to confirm these results in both regular and high-risk patient groups.
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